Oncology professionals are fully aware that the five-year mark of being disease-free after the diagnosis of cancer is not a magical number. Cancer is now considered a chronic disease and recurrence can happen at any time, which is unexpected and frightening. Yet, for me, and for many other cancer survivors, the five-year mark is one to be celebrated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1188/13.CJON.341 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Head and neck cancer surveillance: A guide past the five-year mark.
Aust J Gen Pract
December 2024
MB BChir (Cantab), MA (Med) (Cantab), FRCS (Eng), FRACS (OHNS), Consultant Otolaryngologist, Head and Neck Surgeon, Royal Brisbane and Women@s Hospital/Surgical, Treatment and Rehabilitation Service, Brisbane, Qld; Deputy Director of Surgery, Surgical, Treatment@and Rehabilitation Service, Brisbane, Qld; Adjunct Associate Professor, Griffith Institute of Drug Discovery, Griffith University, Brisbane, Qld; Senior Academic Lecturer, School of Clinical Medicine, The@University of Queensland, Brisbane, Qld.
Background: A head and neck cancer patient has completed treatment and five-year surveillance with their oncologists and surgeons and has been discharged back into your care. What is next and what do you not want to miss in this patient?
Objective: This article aims to provide the general practitioner with a practical guide and an up-to-date evidence-based review on how to manage the head and neck cancer survivor.
Discussion: Attentive surveillance encompassing risk stratification and guidance, early detection of recurrence and second malignancies, effective management of chronic symptoms and the provision of psychosocial support are fundamental in providing a holistic and comprehensive care plan for the head and neck cancer survivor.
Unraveling the Prognostic Role of t(1:19) in Pediatric Pre-B Acute Lymphoblastic Leukemia: Insights from a Saudi Nationwide Cohort.
Cancer Genet
November 2024
Department of Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia; Hematology Department, Faculty of Medicine, King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia; Hematology Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Recurrent translocation t(1;19) (q23;p13) describes a unique cytogenetic group of childhood B-cell acute lymphoblastic leukemia (ALL). Historically, t(1;19)(q23;p13.3) has been associated with poor outcomes.
View Article and Find Full Text PDFExploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma.
Cancer Drug Resist
October 2024
Department of Hematology Oncology, UT Health Science Center San Antonio, San Antonio, TA 78229, USA.
Melanoma is the most aggressive form of skin cancer, characterized by a poor prognosis, and its incidence has risen rapidly over the past 30 years. Recent therapies, notably immunotherapy and targeted therapy, have significantly improved the outcome of patients with metastatic melanoma. Previously dismal five-year survival rates of below 5% have shifted to over 50% of patients surviving the five-year mark, marking a significant shift in the landscape of melanoma treatment and survival.
View Article and Find Full Text PDFIdentification of alarm pheromone components of the southern giant Asian hornet, Vespa soror, a major pest of honey bees.
Insect Sci
September 2024
CAS Key Laboratory of Tropical Forest Ecology, Xishuangbanna Tropical Botanical Garden, Chinese Academy of Sciences, Kunming, China.
Article Synopsis
- * Our research identified five key compounds in the sting venom of V. soror, which act as alarm pheromones that trigger defensive reactions in both hornets and honey bees.
- * The study raises intriguing questions about the potential manipulation of bee behavior by V. soror, suggesting a complex evolutionary arms race involving alarm cues and defensive strategies.
Comprehensive health status and health-related quality of life of children at diagnosis of high-risk neuroblastoma: a multicentric pilot study.
Hematol Transfus Cell Ther
December 2024
McMaster Children's Hospital, Hamilton, Canada.
Background: Neuroblastomas account for 8-10 % of all cancer diagnoses among children. Most patients present with advanced, high-risk disease and 90 % are less than five years old. The burden of morbidity and mortality is high and is quantifiable by measures of health-related quality of life (HRQL).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!